



I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 596703625 US, on the date shown below in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: October 5, 2006

Signature:

*Rosemarie Puljic-Salmeron*  
(Rosemarie Puljic-Salmeron)

Patent

Docket No. 282172000602

Client Reference No.: 4900.20

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

David COOK et al.

Serial No.: 10/803,109

Filing Date: March 17, 2004

For: METHODS FOR QUENCHING  
PATHOGEN INACTIVATORS IN  
BIOLOGICAL MATERIALS

Confirmation No.: 5306

Examiner: S. Saucier

Group Art Unit: 1651

### INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. A copy of U.S. Patent number 27 is not submitted herewith. Copies of the remaining documents cited in the attached Form PTO/SB/08a/b were previously submitted in an Information Disclosure Statement and/or Office Action directed to related applications Serial Number 09/110,776, filed July 6, 1998 (now U.S. Patent No. 6,270,952) and/or Serial Number 09/912,031, filed July 23, 2001 (now U.S. Patent No. 6,709,810), and accordingly copies are not included herewith. This protocol conforms with 37 C.F.R. § 1.98(d) and M.P.E.P. 609(A)(2). The Examiner is requested to make these documents of record in the application.

This Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
  - ☐ A fee is required. A check in the amount of \_\_\_ is enclosed.
  - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
  - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
  - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of \_\_\_ is enclosed.
  - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist;

(iii) the information, protocols, results and the like reported by third parties are accurate or enabling;  
or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petition and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 282172000602.

Dated: October 5, 2006

Respectfully submitted,

By

  
Alicia J. Hager

Registration No.: 44,140

MORRISON & FOERSTER LLP  
755 Page Mill Road  
Palo Alto, California 94304-1018  
(650) 813-4296



ALTERNATIVE TO PTO/SB/08a/b (07-05)

<b>Substitute for form 1449/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/803,109
				Filing Date	March 17, 2004
				First Named Inventor	David COOK
				Art Unit	1651
Sheet	1	of	5	Examiner Name	S. Saucier
				Attorney Docket Number	282172000602

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	1.	US-2,402,665-A	06-25-1946	Peppel et al.	
	2.	US-4,252,645-A	02-24-1981	Marconi et al.	
	3.	US-4,337,269-A	06-29-1982	Berke et al.	
	4.	US-4,727,027-A	02-23-1988	Wiesehahn et al.	
	5.	US-4,748,120-A	05-31-1988	Wiesehahn et al.	
	6.	US-4,944,920-A	07-31-1990	Rubinstein	
	7.	US-4,971,760-A	11-20-1990	Rubinstein	
	8.	US-5,055,485-A	10-08-1991	Geacintov et al.	
	9.	US-5,094,960-A	03-10-1992	Bonomo	
	10.	US-5,120,649-A	06-09-1992	Horowitz et al.	
	11.	US-5,232,844-A	08-03-1993	Horowitz et al.	
	12.	US-5,281,579-A	01-25-1994	Estep	
	13.	US-5,418,130-A	05-23-1995	Platz et al.	
	14.	US-5,559,250-A	09-24-1996	Cook et al.	
	15.	US-5,587,490-A	12-24-1996	Goodrich Jr. et al.	
	16.	US-5,591,350-A	01-07-1997	Piechocki et al.	
	17.	US-5,601,730-A	02-11-1997	Page et al.	
	18.	US-5,637,451-A	06-10-1997	Ben-Hur et al.	
	19.	US-5,658,722-A	08-19-1997	Margolis-Nunno et al.	
	20.	US-5,660,731-A	08-26-1997	Piechocki et al.	
	21.	US-5,691,132-A	11-25-1997	Wollowitz et al.	
	22.	US-5,753,258-A	05-19-1998	Schreier et al.	
	23.	US-6,093,725-A	07-25-2000	Cook et al.	
	24.	US-6,136,586-A	10-24-2000	Budowsky	
	25.	US-6,150,109-A	11-21-2000	Edson et al.	
	26.	US-6,270,952-B1	08-07-2001	Cook et al.	
	27.	US-6,709,810-B2	03-23-2004	Cook et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>d</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	28.	EP-0 352 076-A2,B1	01-24-1990	The University of British Columbia		
	29.	EP-0 457 196-A2	11-21-1991	New York Blood Center, Inc.		
	30.	EP-0 641 796-A1	03-08-1995	The University of British Columbia		
	31.	WO-95/00631-A1	01-05-1995	New York Blood Center, Inc.		
	32.	WO-96/02838-A1	02-01-1996	Forskarpatent I Linköping AB		
	33.	WO-96/09846-A1	04-04-1996	Aradigm Corporation		
	34.	WO-96/14737-A1	05-23-1996	Steritech, Inc.		
	35.	WO-96/39816-A1	12-19-1996	Credit Managers Association of California		
	36.	WO-96/39818-A1	12-19-1996	Cerus Corporation		
	37.	WO-96/40857-A1	12-19-1996	Steritech, Inc.		
	38.	WO-97/02028-A1	01-23-1997	Hemasure, Inc.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

pa-1100204

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/803,109
				Filing Date	March 17, 2004
				First Named Inventor	David COOK
				Art Unit	1651
				Examiner Name	S. Saucier
Sheet	2	of	5	Attorney Docket Number	282172000602

	39.	WO-97/07674-A1	03-06-1997	Pentose Pharmaceuticals, Inc.	
	40.	WO-97/16966-A1	05-15-1997	New York Blood Center, Inc.	
	41.	WO-97/18844-A1	05-29-1997	Pall Corporation	
	42.	WO-98/30545-A1	07-16-1998	Cerus Corp.	
	43.	WO-99/34839-A1	07-15-1999	Cerus Corp.	

\*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
	44.	Aejmelaeus et al. (1996). "Is There an Unidentified Defense Mechanism Against Infection in Human Plasma," <i>FEBS Letters</i> 384:128-130.			
	45.	Al-Harbi et al. (1997). "Gentamycin and Cyclosporine Increase Total Soluble thiols in the Plasma and Lymphocytes of Rats and Perturb Erythrocyte Rigidity," <i>Med. Sci. Res.</i> 25:155-157.			
	46.	Awasthi et al. (1984). "Purification and Characterization of a New Form of Glutathione S-Transferase from Human Erythrocytes," <i>Biochemical and Biophys. Res. Commun.</i> 125:1053-1060.			
	47.	Baxt et al. (1976). "Mechanisms of Vesicular Stomatitis Virus-Induced Cytopathic Effects," <i>Virology</i> 72:383-392.			
	48.	Begleiter et al. (196). "Chlorambucil in Chronic Lymphocytic Leukemia: Mechanism of Action," <i>Leukemia and Lymphoma</i> 23:187-201.			
	49.	Beutler et al. (1982). "The Role of Bone Marrow Transplantation in the Treatment of Acute Leukemia in Remission," <i>Blood</i> 59:1115-1117.			
	50.	Bolton et al. (1993). "Kinetic Analysis of the Reaction of Melphalan with Water, Phosphate, and Glutathione," <i>Drug Metab. Dispos.</i> 21:986-9996.			
	51.	Bolton et al. (1991). "Specificity of Isozymes of Murine Hepatic Glutathione S-transferase for the Conjugation of Glutathione with L-Phenylalanine Mustard," <i>Cancer Research</i> 51:2410-2415.			
	52.	Bonadonna et al. (1964). "Protection Studies with Sodium Thiosulfate Against Methyl bis-(J-Chloroethyl)amine Hydrochloride (HN2) and its Ethylenimonium Derivative," <i>Clin. Pharm. &amp; Thera.</i> 6:50-64.			
	53.	Budowsky et al. (1996). "Principles of Selective Inactivation of the Viral Genome: Dependence of the Rate of Viral RNA Modification of the Number of Protonizable Groups in Ethyleneimine Oligomers," (1996). <i>Vaccine Res.</i> 5:29-39.			
	54.	Chong et al. (1990). "Evaluation of Thiol Borth for the Culture of Salmonella Typhi and other Bacteris from Blood," <i>Yonsei Medical Journal</i> 31:163-167.			
	55.	Colvin et al. (1993). "Role of Glutathione in Cellular Resistance to Alkylating Agents," <i>Adv. Enzyme Regul.</i> 33:19-26.			
	56.	Colvin et al. (1976). "Alkylating Properties of Phosphoramidate Mustard," <i>Cancer Res.</i> 36:1121-1126.			
	57.	Davey et al. (1992). "The Effect of Prestorage Irradiation Posttransfusion Red Cell Survival," <i>Transfusion</i> 32:525-528.			
	58.	Dern et al. (1967). "Studies on the Preservation of Human Blood. II. The Relationship of Erythrocyte Adenosine Triphosphate Levels and other In Vitro Measures to Red Cell			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/803,109
				Filing Date	March 17, 2004
				First Named Inventor	David COOK
				Art Unit	1651
				Examiner Name	S. Saucier
Sheet	3	of	5	Attorney Docket Number	282172000602

		Storageability," <i>J. Lab &amp; Clin Med.</i> 69:968-978.	
59.		Dirr et al. (1994). "X-Ray Crystal Structures of Cytosolic glutathione S-transferases Implications for Protein Architecture, Substrate Recognition and Catalytic Function," <i>Eur. J. Biochem.</i> 220:645-661.	
60.		Dirven et al. (1996). "Glutathione Conjugation of Alkylating Cytostatic Drugs with a Nitrogen Mustard Group and the Role of Glutathione S-Transferases," <i>Chem. Res. Toxicol.</i> 9:350-360.	
61.		Dirven et al. (1995). "Glutathione Conjugation of the Cytostatic Drug Ifosfamide and the Role of Human Glutathione S-transferases," <i>Chem. Res. Toxicol.</i> 8:979-986.	
62.		Dirven et al. (1994). "The Interaction of Glutathione with 4-Hydroxycyclophosphamide and Phosphoramidate Mustard, Studies by 31P Nuclear Magnetic Resonance Spectroscopy," <i>Chem. Bio. Interact.</i> 93:185-196.	
63.		Dirven et al. (1995). "The Role of Human Glutathione S-transferases Isoenzymes in the Formation of Glutathione Conjugates of the Alkylating Cytostatic Drug Thiopeta," <i>Cancer Res.</i> 55:1701-1706.	
64.		Dorr, R. T. (1991). "Chemoprotectants for Cancer Chemotherapy," <i>Semin. Oncol.</i> 18:48-58.	
65.		Dulik et al. (1990). "Characterization of Glutathione Conjugates of Chlorambucil by Fast Atom Bombardment and Thermospray Liquid Chromatography/mass Spectrometry," <i>Biomed. Environ. Mass Spectrom.</i> 19:248-252.	
66.		Dulik et al. (1986). "Characterization of Melphalan-Glutathione Adducts whose Formation is Catalyzed by Glutathione Transferases," <i>Biochem. Pharmacol.</i> 35:3405-3409.	
67.		Dulik et al. (1987). "Conversion of Melphalan to 4-(Glutathionyl)Phenylalanine. A Novel Mechanism for Conjugation by Glutathione-S-transferases," <i>Drug Metab. Dispos.</i> 15:195-199.	
68.		Fasth et al. (1973). "Protective Effect of Thiosulfate and metabolic Thiosulfate Precursors Against Toxicity of Nitrogen Mustard (HN2)" <i>Biochem. Pharmacology</i> 22:1337-1351.	
69.		Gamcsik et al. (1997). "Kinetics of the Conjugation of Aniline Mustards with Glutathione and Thiosulfate," <i>Chem. Biol. Interact.</i> 105:35-52.	
70.		Gao et al. (1991). "A Novel Cationic Liposome Reagent for Efficient Transfection of Mammalian Cells," <i>Biochem. Biophys. Res. Commun.</i> 179:280-285.	
71.		Gao et al. (1993). "Cytoplasmic Expression of a Reporter Gene by Co-Delivery of T7 RNA Polymerase and T7 Promoter Sequence with Cationic Liposomes," <i>Nucleic Acids Res.</i> 21:2867-2872.	
72.		Gao, et al. (1996). "Potentiation of Cationic Liposome-Mediated Gene Delivery by Polycations," <i>Biochemistry</i> 35:1027-1036.	
73.		Gourdie, T. A. (1991). "Synthesis and Evaluation of DNA-targeted Spatially Separated Bis(aniline mustards) as Potential Alkylating Agents with Enhanced DNA Cross-Linking Capability," <i>J. Med. Chem.</i> 34(1):240-248.	
74.		Greenwalt et al. (1990). "Studies in Red Blood Cell Preservation: 3.A Phosphate-Ammonium-Adenine Additive Solution," <i>Vox San</i> 58:94-99.	
75.		Guenther et al. (1992). "Direct Measurement of Melphalan Conjugation with Glutathione: Studies with Human Melanoma Cells and Mammalian Liver," <i>J. Pharmacol. Exp. Ther.</i> 260:1331-1336.	
76.		"Guidelines for Prevention of Transmission of Human Immunodeficiency Virus and Hepatitis B Virus to Health-Care and Public Safety Workers," (June 29, 1989). Morbidity and Mortality Weekly Report, Centers for Disease Control, Atlanta, Georgia, Vol. 38, No. S-6 pp. 1; 3-37. (Page 2 Blank).	
77.		Hageman et al. (1997). "Reducing Effects of Garlic Constituents on DNA Adduct Formation in Human Lymphocytes In Vitro," <i>Nutrition and Cancer</i> 27:177-185.	
78.		Hanson et al. (1990). "Application of a Rapid Microplaque Assay for Determination of Human Immunodeficiency Virus Neutralizing Antibody Titers," <i>J. Clin. Microbio.</i> 28:2030-2034.	
79.		Hogman et al. (1991). "Storage of Saline-Adenine-Glucose-Mannitol-Suspended Red Cells in a new Plastic Container: Polyvinylchloride Plasticized with Butyryl-n-Trihexyl-Citrate," <i>Transfusion</i> 31:26-29.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

pa- 1100204

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/803,109
				Filing Date	March 17, 2004
				First Named Inventor	David COOK
				Art Unit	1651
				Examiner Name	S. Saucier
Sheet	4	of	5	Attorney Docket Number	282172000602

80.	Hogman et al. (1993). "Half-Strength Citrate CPD Combined with a New Addictive Solution for Improved Storage of Red Blood Cells Suitable for Clinical Use," <i>Vox Sang</i> 65:271-278.
81.	"K Irradication of Cellular Blood Components for Prevention of TA-GVHD," <i>Clinical Practice of Transfusion Medicine (Graft-Verus Host Disease)</i> , pp. 939-940.
82.	Kawabata et al. (1990). "Mechanisms of in vitro Immunosuppression by Hepatocyte-Generated Cyclophosphamide Metabolites and 4-Hydroxycyclophosphamide," <i>Biochem. Pharmacol.</i> 40:927-935.
83.	Koch et al. (1996). "Effects of N-Acetylcysteine on Bacterial Clearance," <i>European J. of Clin. Invest.</i> 26:884-892.
84.	Lasic D. D. (1997). "Liposomes," <i>Liposomes in Gene Delivery</i> CRC Press, Boca Ration, FL Chapter 6, pp. 67-112.
85.	LoGrippe et al. (1958). "Chemical and Combined Methods for Plasma Sterilization," - <i>Proceedings of the Sixth Congress of the Int'l. Soc. of Blood Transfusion Bibliotheca Haematologica</i> (Hollander, ed), pp. 225-230.
86.	Malmberg et al. (1979). "Effect of Increased Blood-Oxygen Affinity on Oxygen Transport in Hemorrhagic Shock," <i>J. Appl. Physiol. Respirat Environ. Exercise Physiol.</i> 47:889-895.
87.	Mangels et al. (1978). "Quantitative Evaluation of Three Commercial Blood Culture Media for Growth of Anaerobic Organisms," <i>J. of Clin. Microbiology</i> 7:59-62.
88.	Marcus et al. (1994). "Cell Killing by Viruses: 1. Comparison of Cell-Killing Plaque-Forming, and Defective-Interfering Particles of Vesicular Stomatitis Virus," <i>Virology</i> 57:321-338.
89.	Mulder et al. (1997). "Modulation of Glutathione Conjugation in Vivo: How to Decrease Glutathione Conjugation in vivo or in Intact Cellular Systems in Vitro," <i>Chem. Biol. Interact.</i> 105:17-34.
90.	Popovic et al. (1984). "Detection, Isolation, and Continuous Production of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and Pre-AIDS," <i>Science</i> 224:497-500.
91.	Roth Jr. et al. (1987). "Survival Rates and Properties of Sickel Cell Anemai Red Cells Treated with Nitrogen Mustard," <i>Pathophysiological Aspects of Sickle Cell Vaso-Occlusion</i> , pp. 245-261.
92.	Rywkin et al. (1992). "Importance of Type I and Type II Mechanisms in the Photodynamic Inactivation of Viruses in Blood with Aluminium Phthalocyanine Derivatives," <i>Photochemistry and Photobiology</i> 56:463-469.
93.	Simon (1977). "Adenine in Blood Banking," <i>Transfusion</i> 17:317-325.
94.	Song, P.-S. et al. (1979). "Review Article," <i>Photochem. and Photobio.</i> 29:1177-1197.
95.	Special Reagents for Thiol Groups. (1971). <i>Aldrichimica acta</i> , Aldrich Chemical Co. Inc. (Publisher) 4:33-35, 46-48.
96.	Szinicz et al. (1981). "Effects of Various Compounds on the Reaction of Tris-(2-chloroethyl)amine with Ribonucleic Acid In Vitro and on its Toxicity in Mice," <i>Arzneimittel-Forschung</i> 31:1713-1717.
97.	Tew (1994). "Glutathione-Associated Enzymes in Anticancer Drug Resistance," <i>Cancer Research</i> 54:4313-4320.
98.	Wagner et al. (1993). "Red Cell Alterations Associated with Virucidal Methylene Blue Phototreatment," <i>Transfusion</i> 33:30-36.
99.	Watson et al. "Kinetics of Phosphormide Mustard Hydrolysis in Aqueous Solution," <i>J. Pharm. Sci.</i> 74:1283-1292.
100.	Wedner et al. (1985). "Inhibition of Lectin-Induced Lymphocyte Activation by 2-cyclohexene-1-One: Analysis of DNA Synthesis in Individual Cells by BUdR Quenching of Hoechst 33258," <i>Int. J. Immunopharmac.</i> 7:25-30.
101.	Weinberg et al. (1984). "Effectiveness of the Antimicrobial Removal Device, BACTEC 16B Medium and Thiol Broth in Neutralizing Antibacterial Activities of Imipenem, Norfloxacin, and Related Agents," <i>J. of Clin. Microbiology</i> 19:207-209.
102.	Woodson, R. D. "Physiological Significance of Oxygen Dissociation Curve Shifts," <i>Critical Care Medicine</i> 7:368-373.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/803,109
				Filing Date	March 17, 2004
				First Named Inventor	David COOK
				Art Unit	1651
				Examiner Name	S. Saucier
Sheet	5	of	5	Attorney Docket Number	282172000602

	103.	Yuan et al. (1991). "Glutathione Conjugation with Phosphoramidate Mustard and Cyclophosphamide. A Mechanistic Study Using Tandem Mass Spectrometry," <i>Drug Metab. Dispos.</i> 19:625-629.	
--	------	---	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--